Salarius trims burn, seeks Decoy merger and emergency financing amid cash shortfall, Nasdaq risk

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) - snapshot

What's happening inside: management has sharply cut R&D and G&A costs, pursued a strategic merger with Decoy Therapeutics and an equity line (ELOC) to raise cash, but the company remains a pre‑revenue clinical-stage biotech with going‑concern risk and Nasdaq listing pressure.

Key points & statistics
* Cash and cash equivalents: $794,886 at June 30, 2025 (was $2,434,528 at Dec 31, 2024).
* Total assets: $1,392,778 (Dec 31, 2024: $3,022,974).
* Total liabilities: $2,222,502 (Dec 31, 2024: $1,511,279).
* Stockholders' equity (deficit): $(829,724) at June 30, 2025 (was $1,511,695 at Dec 31, 2024).
* Accumulated deficit: $(84,590,976) at June 30, 2025.
* Common shares issued/outstanding: 2,127,286 at June 30, 2025 (1,441,157 at Dec 31, 2024) - post reverse 1‑for‑8 split adjusted.
* Three months ended June 30, 2025: Net loss $ (957,825) vs $(1,424,433) in 2024.
* Six months ended June 30, 2025: Net loss $ (2,667,358) vs $(3,139,723) in 2024.
* Loss per share - three months: $(0.45) (2025) vs $(2.37) (2024); six months: $(1.41) (2025) vs $(5.62) (2024).
* Operating cash used (six months): $(2,044,011) vs $(2,426,147) prior year.
* Subsequent financing: Issued 5,518,308 shares for $3.8M (post‑period ELOC draw); company states cash ≈ $3.4M as of filing date.

Positive aspects of the income statement
* Reduced cash burn: Total operating expenses for six months dropped to $2.684M (2025) from $3.239M (2024) - an improvement of ~$0.55M.
* Lower R&D spend: Six‑month R&D fell to $191,915 (2025) from $457,449 (2024) as company curtailed sponsored trials and reduced personnel.
* Lower G&A: Six‑month G&A declined to $2.492M (2025) from $2.782M (2024), reflecting cost‑savings measures.
* Net loss narrowed vs prior year periods (both quarter and six months), driven by expense cuts.

Negative aspects of the income statement and related financials
* Still unprofitable: Net loss of $2.667M for six months; no revenue - company remains pre‑revenue.
* Very limited cash runway at quarter‑end: $0.8M cash (June 30, 2025) and working capital deficit (company reported working capital ≈ $(0.9)M).
* High accumulated deficit: $(84.6)M - long history of losses and no commercial products.
* Equity dilution risk: Significant share issuances under ATM and ELOC; weighted average shares rose sharply (1.89M six‑month 2025 vs 558k 2024), compressing per‑share metrics and diluting holders.
* Reliance on non‑recurring financing/events: income statement relief is from cost cuts, not from commercial revenue - ongoing viability depends on financings or the planned merger.

Corporate actions, milestones and risks to watch
* Merger with Decoy Therapeutics entered Jan 10, 2025; multiple amendments reduced Salarius legacy ownership to ~7.6% (Amendment No. 2) and added complex preferred stock mechanics (anti‑dilution protections, conversion conditions). Closing requires a Qualified Financing of at least $6.0M.
* ELOC activity: December 2024 ELOC used post‑period to raise ~$3.5-3.8M (July issuances). Company reported proceeds and commitment shares; lifting of exchange cap approved July 8, 2025 special meeting.
* Nasdaq risk: Received deficiency notices for minimum bid price and stockholders' equity; appealed and obtained Hearings Panel extensions requiring staged milestones (equity standard and $1.00 minimum bid deadlines in mid/late Aug 2025). Failure to meet them could lead to delisting.
* Going concern: Management states "substantial doubt" about ability to continue without additional financing or the Merger; if Merger or financing fails, liquidation is a potential outcome.
* Non‑cash and one‑time items: Warrant cancellation ($350k paid for cancellation), deferred offering costs and accrued issuance costs ($356,984) impact equity and cash dynamics.

Bottom line - what investors should watch next
* Cash runway and financing execution: monitor cash balance updates after ELOC draws and any additional financings (Qualified Financing $6M requirement for Merger).
* Merger progress and terms: amendments materially shift control and dilution; track closing conditions, conversion mechanics, and any further dilution from Qualified Financing.
* Nasdaq compliance: timely evidence of regained equity and minimum bid price is critical - delisting risk remains a live event.
* Operational outlook: R&D curtailed and reliant on investigator‑initiated data (MD Anderson) - future clinical decisions hinge on data availability and fresh capital.

Summary: Salarius (NASDAQ: SLRX) is actively reducing burn and pursuing a merger and equity draws to avoid insolvency and delisting. Income‑statement trends show meaningful cost cuts and a narrower loss, but the company remains cash‑constrained, pre‑revenue, and dependent on near‑term financings and Merger execution. Short‑term shareholder outcomes will be decided by the success of the Qualified Financing, final terms and timing of the Decoy merger, and Nasdaq compliance milestones.